Log In
BCIQ
Print this Print this
 

AMG 139, MEDI2070

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionHuman mAb against interleukin-23 (IL-23)
Molecular Target Interleukin-23 (IL-23)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationCrohn's disease
Indication DetailsTreat Crohn's disease
Regulatory Designation
PartnerAllergan plc;
AstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,520.0M

$300.0M

$1,270.0M


 Deals Details
Get a free BioCentury trial today